Sanofi/GSK restart COVID-19 vaccine trials after tweaking formulation
pharmaphorum
FEBRUARY 22, 2021
The vaccine is based around an adjuvanted recombinant protein, which will be tested in a new phase 2 study to assess the response including in older adults. But instead rivals such as BioNTech/Pfizer, AstraZeneca and Moderna have made it to market first with their vaccines.
89 
Let's personalize your content